Skip to content

Categorydrug safety

Discovery of new drug targets for memory impairment in Alzheimer’s Disease.

Discovery of new drug targets for memory impairment in Alzheimer’s Disease. A study from KIST has revealed the novel mechanism of how Alzheimer’s patients might lose their memory. The researchers also propose new therapeutic targets, which include GABA production and release mechanisms in reactive astrocytes for treatment of Alzheimer’s disease. Furthermore, we provide a stepping stone for the development of MAO-B inhibitors with long lasting efficacy.

Thoughts health innovators?

Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment.

Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment. Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events. The study highlights gaps in how the long-term safety of drugs intended for chronic use in children is assessed as part of the FDA approval process.

Thoughts health innovators?